Edwards Lifesciences has revealed that it will be developing a new manufacturing facility in Draper, Utah, which will enable it to expand its manufacturing and R&D capability.
The company said that as the first step of its planned expansion, it will transfer manufacturing of its cannula and embolic protection devices (utilised by cardiac surgeons during open-heart surgery) from its existing Midvale, Utah facility to the new facility in Draper in the first half of 2010.
Paul Redmond, corporate vice president of global corporate operations at Edwards, said: “Our new facility will allow us to evolve our world class operations to support Edwards’ long-term global product supply strategy. We are very grateful to the Governor’s Office of Economic Development in Utah and the Draper City Council for their extraordinary efforts in working with us to ensure our success in creating a stronger and more customer-focused company, poised for even more growth in the future.”
Headquartered in Irvine, California, Edwards Lifesciences treats advanced cardiovascular disease with its heart valve therapies, and critical care and vascular technologies, which are sold in approximately 100 countries. The company’s brands include, Carpentier-Edwards, Cosgrove-Edwards, Edwards Sapien, FloTrac, Fogarty, Perimount Magna and Swan-Ganz.